58 studies found for:
"spinocerebellar ataxia type 3" OR "Spinocerebellar Ataxias"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Completed |
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
|
||||
| 2 | Recruiting |
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
|
||||
| 3 | Withdrawn |
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
|
||||
| 4 | Completed |
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
|
||||
| 5 | Recruiting |
Dalfampridine and Gait in Spinocerebellar Ataxias
|
||||
| 6 | Recruiting |
Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
|
||||
| 7 | Active, not recruiting |
RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
|
||||
| 8 | Completed |
Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias
|
||||
| 9 | Active, not recruiting |
Biomarkers in Autosomal Dominant Cerebellar Ataxia
|
||||
| 10 | Active, not recruiting |
Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
|
||||
| 11 | Completed |
Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
|
||||
| 12 | Completed |
Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
|
||||
| 13 | Completed |
A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
||||
| 14 | Completed |
Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
||||
| 15 | Completed |
Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)
|
||||
| 16 | Completed |
High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
|
||||
| 17 | Completed |
Coenzyme Q10 in Adult-Onset Ataxia
|
||||
| 18 | Completed |
A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
||||
| 19 | Enrolling by invitation |
4-Aminopyridine in Episodic Ataxia Type 2
|
||||
| 20 | Unknown † |
Characteristics of Episodic Ataxia Syndrome
|
† Indicates status has not been verified in more than two years
